285 related articles for article (PubMed ID: 19739006)
1. Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment.
Vélez ID; Colmenares LM; Muñoz CA
Rev Inst Med Trop Sao Paulo; 2009; 51(4):231-6. PubMed ID: 19739006
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of visceral leishmaniasis in children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
[TBL] [Abstract][Full Text] [Related]
3. [Resistance of Leishmania infantum to Glucantime: risk factors and therapeutic management].
Piarroux R; Garnier JM; Gambarelli F; Dumon H; Kaplanski S; Unal D
Arch Pediatr; 1996 Apr; 3(4):352-6. PubMed ID: 8762958
[TBL] [Abstract][Full Text] [Related]
4. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation.
Berhe N; Ali A; Hailu A; Yeneneh H
Acta Trop; 1994 Jun; 57(1):83-90. PubMed ID: 7942358
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of infantile visceral leishmaniasis].
Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
[TBL] [Abstract][Full Text] [Related]
6. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
7. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
Gramiccia M; Gradoni L; Orsini S
Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
[TBL] [Abstract][Full Text] [Related]
8. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
[TBL] [Abstract][Full Text] [Related]
9. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
Carrió J; Portús M
BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
[TBL] [Abstract][Full Text] [Related]
12. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis.
Pourabbas B; Ghadimi Moghadam A; Pouladfar G; Rezaee Z; Alborzi A
Am J Trop Med Hyg; 2013 May; 88(5):868-71. PubMed ID: 23400573
[TBL] [Abstract][Full Text] [Related]
13. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
14. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
[TBL] [Abstract][Full Text] [Related]
15. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy.
Cascio A; Gradoni L; Scarlata F; Gramiccia M; Giordano S; Russo R; Scalone A; Camma C; Titone L
Am J Trop Med Hyg; 1997 Jul; 57(1):75-8. PubMed ID: 9242323
[TBL] [Abstract][Full Text] [Related]
16. [Visceral leishmaniasis: new drugs].
Minodier P; Robert S; Retornaz K; Garnier JM
Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
[TBL] [Abstract][Full Text] [Related]
17. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate.
Utili R; Rambaldi A; Tripodi MF; Andreana A
Infection; 1995; 23(3):182-3. PubMed ID: 7499009
[TBL] [Abstract][Full Text] [Related]
18. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
Minodier P; Retornaz K; Horelt A; Garnier JM
Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
[TBL] [Abstract][Full Text] [Related]
20. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
